ICAD, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021 and for the Full Year 2021
January 04, 2022 at 08:00 am
Share
iCAD, Inc. provided revenue guidance for the fourth quarter of 2021 and for the full year 2021. Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter of 2021 to be between $7.8 and $8.0 million.
The total revenue for the full year 2021 to be approximately $33.6 to $33.8 million.
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogramâs collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a womanâs breast anatomy from the mammogram image.